Our Pipeline

Reimagining GPCR targets as therapies for untreated fibrotic disease

GPCRs are recognized as highly druggable receptors with untapped potential in fibrosis therapy. At Telescope Therapeutics, our discovery platform includes three powerful aspects:

GPCR-Centric
Platform

A world-class team with deep expertise in GPCRs, enabling us to rediscover and target underexplored GPCRs or location bias for established targets

Human-Relevant
Models

Leveraging our core strengths in cardiology and stem cell biology, we deploy human iPSC-derived models of fibrosis

Biosensor-Enabled Mechanistic Profiling

Integrating FRET-based biosensors into our platforms allows real-time tracking of critical receptor-dependent signaling events across the cell.

Program
Target
Indication
Discovery
Preclinical
IND enabling
Phase 1
Phase 2
TT101
Urotensin Receptor
Cardiac Fibrosis
TT102
Urotensin Receptor
Chronic Kidney Disease
TT201
Angiotensin Receptor
Cardiac Fibrosis